This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG CI
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients CI
Heart Test Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
Heart Test Laboratories, Inc. Appoints Partho P. Sengupta to Its Scientific Advisory Board CI
Heart Test Laboratories, Inc. Appoints Jordan B. Strom to Its Scientific Advisory Board CI
HeartSciences Appoints Benjamin Glicksberg to its Scientific Advisory Board CI
Heart Test Laboratories, Inc. has Changed its Name to HeartSciences Inc CI
Heart Test Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023 CI
Heart Test Laboratories, Inc. announced that it has received $0.934997 million in funding CI
Heart Test Laboratories, Inc. announced that it has received $1.085006 million in funding CI
Heart Test Laboratories, Inc. Enters into Multiple Definitive License Agreements with Icahn School of Medicine At Mount Sinai CI
HeartSciences Completes License Agreements on AI Cardiovascular Algorithms With Icahn School of Medicine at Mount Sinai MT
Heart Test Laboratories, Inc. announced that it expects to receive $0.934997 million in funding CI
Heart Test Laboratories, Inc. announced that it expects to receive $1.085006 million in funding CI
Heart Test Laboratories, Inc. Announces That Its Myovista® Wavecgtm Has Been Selected by Cardiact Ltd (?Cardiact?) to Be Used in Its Heart Screening Program of Members of the Association of Garda Sergeants and Inspectors CI
Heart Test Laboratories, Inc. announced that it has received $1 million in funding CI
Sector Update: Health Care Stocks Lower Late Afternoon MT
Sector Update: Health Care Stocks Mixed Monday Afternoon MT
Heart Test Laboratories Files for $50 Million Mixed Shelf; Shares Drop MT
Heart Test Laboratories, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023 CI
Heart Test Laboratories, Inc. announced that it expects to receive $1 million in funding CI
Heart Test Laboratories Has Distribution Accord With Denmark's FJ Medical MT
Heart Test's MyoVista wavECG Selected by PanaceaFlo for Heart Screening Evaluation Study in Dublin MT
Heart Test Laboratories, Inc. Announces It?s MyoVista wavECGTM Selection to Be Used in Irish Heart Screening Evaluation CI
Heart Test Laboratories Gets Patent Allowance Notice From European Patent Office MT
Chart Heart Test Laboratories, Inc.
More charts
Heart Test Laboratories, Inc., doing business as HeartSciences, is an artificial intelligence electrocardiogram (AI ECG) company. The Company is focused on using AI to transform ECG to save lives through earlier detection of heart disease. The Company’s initial focus is on applying technology to extend the clinical indications for use of an electrocardiograph (ECG) device. Its first device, the MyoVista is an ECG that can be used in a range of clinical settings and provides diagnostic information to a qualified healthcare professional on cardiac dysfunction which has traditionally only been provided using cardiac imaging. In addition, MyoVista provides conventional ECG information. The Company focuses on marketing its device both domestically and internationally to various hospitals, clinics, and medical centers and manufacturing the devices using outsourced production facilities.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0999 USD
Average target price
0.675 USD
Spread / Average Target
+575.68%
Consensus
  1. Stock Market
  2. Equities
  3. HSCS Stock
  4. News Heart Test Laboratories, Inc.
  5. Ascendiant Capital Initiates Heart Test Laboratories at Buy Rating With $3.30 Price Target